Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Sirolimus for pediatric liver transplant recipients with post‐transplant lymphoproliferative disease and hepatoblastoma

Identifieur interne : 001776 ( Istex/Curation ); précédent : 001775; suivant : 001777

Sirolimus for pediatric liver transplant recipients with post‐transplant lymphoproliferative disease and hepatoblastoma

Auteurs : Carolina Jiménez-Rivera ; Yaron Avitzur ; Annie H. Fecteau [Canada] ; Nicola Jones ; David Grant [Canada] ; Vicky Lee Ng

Source :

RBID : ISTEX:33918D917569BF76874372041243AC5DD503C58E

Abstract

Abstract:  Sirolimus is a promising immune suppressive agent, with the potential to reduce calcineurin inhibitor associated nephrotoxicity, halt progression of chronic rejection and prevent tumor proliferation. The aim of this study was to review the experience using sirolimus in pediatric liver transplant recipients at a single center. Database and medical charts of all pediatric liver transplant recipients receiving sirolimus at the Hospital for Sick Children in Toronto were reviewed. Eight patients received sirolimus between October, 2000 and September, 2002. Indications for using sirolimus were post‐transplant lymphoproliferative disease (PTLD) (n = 6) and hepatoblastoma (n = 2). Two patients with PTLD concurrently had renal impairment and chronic rejection. Sirolimus dosages ranged between 1.5 and 5 mg once daily. Median duration of follow‐up was 17 months. Persistently elevated liver transaminase levels in the two children with chronic rejection decreased during sirolimus therapy. Recurrence of PTLD occurred in one patient. Two patients were diagnosed with acute cellular rejection after transition to maintenance sirolimus monotherapy. Resolution of adverse effects including mouth sores (n = 3), leg swelling (n =  2) and hyperlipidemia (n = 3) occurred either spontaneously or with dose reduction. Sirolimus was discontinued in four patients because of persisting bone marrow suppression, interstitial pneumonitis, life‐threatening sepsis and refractory diarrhea. Children with PTLD or hepatoblastoma may benefit from immune suppression with sirolimus after liver transplantation. Further multi‐center, prospective, randomized controlled trials will be instrumental to further the knowledge of long‐term efficacy, safety and tolerability of sirolimus for selected children following liver transplantation.

Url:
DOI: 10.1111/j.1399-3046.2004.00156.x

Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:33918D917569BF76874372041243AC5DD503C58E

Curation

No country items

Carolina Jiménez-Rivera
<affiliation>
<mods:affiliation>Divisions of Pediatric Gastroenterology and Nutrition</mods:affiliation>
<wicri:noCountry code="no comma">Divisions of Pediatric Gastroenterology and Nutrition</wicri:noCountry>
</affiliation>
Yaron Avitzur
<affiliation>
<mods:affiliation>Divisions of Pediatric Gastroenterology and Nutrition</mods:affiliation>
<wicri:noCountry code="no comma">Divisions of Pediatric Gastroenterology and Nutrition</wicri:noCountry>
</affiliation>
Nicola Jones
<affiliation>
<mods:affiliation>Divisions of Pediatric Gastroenterology and Nutrition</mods:affiliation>
<wicri:noCountry code="no comma">Divisions of Pediatric Gastroenterology and Nutrition</wicri:noCountry>
</affiliation>
Vicky Lee Ng
<affiliation>
<mods:affiliation>Divisions of Pediatric Gastroenterology and Nutrition</mods:affiliation>
<wicri:noCountry code="no comma">Divisions of Pediatric Gastroenterology and Nutrition</wicri:noCountry>
</affiliation>

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Sirolimus for pediatric liver transplant recipients with post‐transplant lymphoproliferative disease and hepatoblastoma</title>
<author>
<name sortKey="Jimenez Ivera, Carolina" sort="Jimenez Ivera, Carolina" uniqKey="Jimenez Ivera C" first="Carolina" last="Jiménez-Rivera">Carolina Jiménez-Rivera</name>
<affiliation>
<mods:affiliation>Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</mods:affiliation>
<wicri:noCountry code="no comma">Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</wicri:noCountry>
</affiliation>
<affiliation>
<mods:affiliation>Divisions of Pediatric Gastroenterology and Nutrition</mods:affiliation>
<wicri:noCountry code="no comma">Divisions of Pediatric Gastroenterology and Nutrition</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Avitzur, Yaron" sort="Avitzur, Yaron" uniqKey="Avitzur Y" first="Yaron" last="Avitzur">Yaron Avitzur</name>
<affiliation>
<mods:affiliation>Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</mods:affiliation>
<wicri:noCountry code="no comma">Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</wicri:noCountry>
</affiliation>
<affiliation>
<mods:affiliation>Divisions of Pediatric Gastroenterology and Nutrition</mods:affiliation>
<wicri:noCountry code="no comma">Divisions of Pediatric Gastroenterology and Nutrition</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Fecteau, Annie H" sort="Fecteau, Annie H" uniqKey="Fecteau A" first="Annie H." last="Fecteau">Annie H. Fecteau</name>
<affiliation>
<mods:affiliation>Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</mods:affiliation>
<wicri:noCountry code="no comma">Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</wicri:noCountry>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Division of General Surgery, Hospital for Sick Children, University of Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of General Surgery, Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Jones, Nicola" sort="Jones, Nicola" uniqKey="Jones N" first="Nicola" last="Jones">Nicola Jones</name>
<affiliation>
<mods:affiliation>Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</mods:affiliation>
<wicri:noCountry code="no comma">Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</wicri:noCountry>
</affiliation>
<affiliation>
<mods:affiliation>Divisions of Pediatric Gastroenterology and Nutrition</mods:affiliation>
<wicri:noCountry code="no comma">Divisions of Pediatric Gastroenterology and Nutrition</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Grant, David" sort="Grant, David" uniqKey="Grant D" first="David" last="Grant">David Grant</name>
<affiliation>
<mods:affiliation>Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</mods:affiliation>
<wicri:noCountry code="no comma">Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</wicri:noCountry>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Department of General Surgery, Toronto Hospital, General Division, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of General Surgery, Toronto Hospital, General Division, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Ng, Vicky Lee" sort="Ng, Vicky Lee" uniqKey="Ng V" first="Vicky Lee" last="Ng">Vicky Lee Ng</name>
<affiliation>
<mods:affiliation>Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</mods:affiliation>
<wicri:noCountry code="no comma">Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</wicri:noCountry>
</affiliation>
<affiliation>
<mods:affiliation>Divisions of Pediatric Gastroenterology and Nutrition</mods:affiliation>
<wicri:noCountry code="no comma">Divisions of Pediatric Gastroenterology and Nutrition</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:33918D917569BF76874372041243AC5DD503C58E</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1111/j.1399-3046.2004.00156.x</idno>
<idno type="url">https://api.istex.fr/document/33918D917569BF76874372041243AC5DD503C58E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001776</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001776</idno>
<idno type="wicri:Area/Istex/Curation">001776</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Sirolimus for pediatric liver transplant recipients with post‐transplant lymphoproliferative disease and hepatoblastoma
<ref type="note" target="#fn1">*</ref>
</title>
<author>
<name sortKey="Jimenez Ivera, Carolina" sort="Jimenez Ivera, Carolina" uniqKey="Jimenez Ivera C" first="Carolina" last="Jiménez-Rivera">Carolina Jiménez-Rivera</name>
<affiliation>
<mods:affiliation>Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Divisions of Pediatric Gastroenterology and Nutrition</mods:affiliation>
<wicri:noCountry code="no comma">Divisions of Pediatric Gastroenterology and Nutrition</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Avitzur, Yaron" sort="Avitzur, Yaron" uniqKey="Avitzur Y" first="Yaron" last="Avitzur">Yaron Avitzur</name>
<affiliation>
<mods:affiliation>Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Divisions of Pediatric Gastroenterology and Nutrition</mods:affiliation>
<wicri:noCountry code="no comma">Divisions of Pediatric Gastroenterology and Nutrition</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Fecteau, Annie H" sort="Fecteau, Annie H" uniqKey="Fecteau A" first="Annie H." last="Fecteau">Annie H. Fecteau</name>
<affiliation>
<mods:affiliation>Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</mods:affiliation>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Division of General Surgery, Hospital for Sick Children, University of Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of General Surgery, Hospital for Sick Children, University of Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Jones, Nicola" sort="Jones, Nicola" uniqKey="Jones N" first="Nicola" last="Jones">Nicola Jones</name>
<affiliation>
<mods:affiliation>Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Divisions of Pediatric Gastroenterology and Nutrition</mods:affiliation>
<wicri:noCountry code="no comma">Divisions of Pediatric Gastroenterology and Nutrition</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Grant, David" sort="Grant, David" uniqKey="Grant D" first="David" last="Grant">David Grant</name>
<affiliation>
<mods:affiliation>Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</mods:affiliation>
</affiliation>
<affiliation wicri:level="1">
<mods:affiliation>Department of General Surgery, Toronto Hospital, General Division, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of General Surgery, Toronto Hospital, General Division, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Ng, Vicky Lee" sort="Ng, Vicky Lee" uniqKey="Ng V" first="Vicky Lee" last="Ng">Vicky Lee Ng</name>
<affiliation>
<mods:affiliation>Pediatric Academic Multi‐Organ Transplant (PAMOT) Program</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Divisions of Pediatric Gastroenterology and Nutrition</mods:affiliation>
<wicri:noCountry code="no comma">Divisions of Pediatric Gastroenterology and Nutrition</wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Pediatric Transplantation</title>
<title level="j" type="alt">PEDIATRIC TRANSPLANTATION</title>
<idno type="ISSN">1397-3142</idno>
<idno type="eISSN">1399-3046</idno>
<imprint>
<biblScope unit="vol">8</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="243">243</biblScope>
<biblScope unit="page" to="248">248</biblScope>
<biblScope unit="page-count">6</biblScope>
<publisher>Munksgaard International Publishers</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2004-06">2004-06</date>
</imprint>
<idno type="ISSN">1397-3142</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1397-3142</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Abstract:  Sirolimus is a promising immune suppressive agent, with the potential to reduce calcineurin inhibitor associated nephrotoxicity, halt progression of chronic rejection and prevent tumor proliferation. The aim of this study was to review the experience using sirolimus in pediatric liver transplant recipients at a single center. Database and medical charts of all pediatric liver transplant recipients receiving sirolimus at the Hospital for Sick Children in Toronto were reviewed. Eight patients received sirolimus between October, 2000 and September, 2002. Indications for using sirolimus were post‐transplant lymphoproliferative disease (PTLD) (n = 6) and hepatoblastoma (n = 2). Two patients with PTLD concurrently had renal impairment and chronic rejection. Sirolimus dosages ranged between 1.5 and 5 mg once daily. Median duration of follow‐up was 17 months. Persistently elevated liver transaminase levels in the two children with chronic rejection decreased during sirolimus therapy. Recurrence of PTLD occurred in one patient. Two patients were diagnosed with acute cellular rejection after transition to maintenance sirolimus monotherapy. Resolution of adverse effects including mouth sores (n = 3), leg swelling (n =  2) and hyperlipidemia (n = 3) occurred either spontaneously or with dose reduction. Sirolimus was discontinued in four patients because of persisting bone marrow suppression, interstitial pneumonitis, life‐threatening sepsis and refractory diarrhea. Children with PTLD or hepatoblastoma may benefit from immune suppression with sirolimus after liver transplantation. Further multi‐center, prospective, randomized controlled trials will be instrumental to further the knowledge of long‐term efficacy, safety and tolerability of sirolimus for selected children following liver transplantation.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001776 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001776 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Istex
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:33918D917569BF76874372041243AC5DD503C58E
   |texte=   Sirolimus for pediatric liver transplant recipients with post‐transplant lymphoproliferative disease and hepatoblastoma
}}

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024